Company intelligence / Profile preview

Immune System Key Ltd.

Ownership: Private
Development stage: Phase 2

Overview

Lead compound Nerofe™ has been granted FDA orphan drug status for AML treatment and is currently in phase IIa development. The company is also conducting a second FDA-approved clinical trial for pancreatic cancer and metastatic colorectal cancer at Georgetown University in Washington, D.C.

Therapeutic areas: OncologyImmunology
Modalities: Peptides
Industry: Biotech

Drug pipeline

1 asset

nerofe

Partnerships

Johnson & Johnson Innovation – JLABS (resident company)

Beyond the preview

Go deeper on Immune System Key Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immune System Key Ltd..

Explore the full profile